Home Cart Sign in  
Chemical Structure| 112965-21-6 Chemical Structure| 112965-21-6

Structure of Calcipotriol
CAS No.: 112965-21-6

Chemical Structure| 112965-21-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.

Synonyms: MC 903; Calcipotriene; Sorilux.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Calcipotriol

CAS No. :112965-21-6
Formula : C27H40O3
M.W : 412.60
SMILES Code : O[C@H]1C[C@H](O)C(/C(C1)=C\C=C2[C@]3([H])CC[C@H]([C@H](C)/C=C/[C@H](C4CC4)O)[C@@]3(C)CCC\2)=C
Synonyms :
MC 903; Calcipotriene; Sorilux.
MDL No. :MFCD00866630

Safety of Calcipotriol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HGC-27 cells 500 nM 24 hours Significantly inhibited CAF-induced oxaliplatin resistance PMC9813133
AGS cells 500 nM 24 hours Significantly inhibited CAF-induced oxaliplatin resistance PMC9813133
Human rectal epithelial cells 1 μM 15 hours Calcipotriol reduced crypt cell production rate by 52% from mean (SEM) 5-29(1.18) to 256(0.80)cells/crypt/hour (p<0.01) PMC1375263
HepG2 cells 0.1, 1, 10 nM 2 hours To investigate the impact of CYP3A4 on the VDR-induction ability of 1,25(OH)2D3, results showed that CYP3A4 inhibited the induction of VDR by 1,25(OH)2D3 PMC11830628
C2C12 cells 10 nM 8 days To investigate the effects of vitamin D and testosterone on muscle differentiation, results showed that testosterone enhanced the inducing effects of VD on VDR, AR, P-AKT, PGC1α, Beclin1 and LC3B PMC11830628

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Sod1 knockout mice (SKO) Intraperitoneal injection 60 μg/kg Three times a week, lasting until 28 weeks of age To investigate the effects of Calcipotriol on muscle function, results showed that Calcipotriol restored grip strength in male SKO mice, increased muscle protein synthesis and mitochondrial biogenesis, while decreasing inflammation and atrogenes expression PMC11830628
BALB/c-nude mice Gastric cancer xenograft model Intraperitoneal injection 60 mg/kg Three times a week for 16 days Significantly inhibited tumor growth and enhanced the anti-tumor effect of oxaliplatin PMC9813133
C57BL/6 mice MC903-induced skin inflammation model Topical application 0.5 nmol/ear Daily for 14 days To investigate the protective effect of DMOG on MC903-induced skin inflammation. DMOG significantly attenuated MC903-induced skin inflammation, accompanied by downregulation of TSLP and IL-33. PMC10940402
C57BL/6J mice Form deprivation myopia (FDM) model Intraperitoneal injection 0.1 mg/kg or 0.5 mg/kg Daily injections for 4 weeks To assess the inhibitory effect of Calcipotriol on FDM development. Results showed that Calcipotriol significantly suppressed FDM-induced myopia progression and upregulated scleral Col1α1 gene expression levels. PMC9904334
C57BL/6J mice Nur77 knockout mice Intraperitoneal injection 60 µg/kg Three times a week for a total of 12 weeks Calcipotriol combined with iBRD9 treatment reduced the body weight and body fat percentage in Nur77 knockout mice, regulated the gut microbiota, improved intestinal mucosal barrier function, reduced LPS absorption into the blood, and alleviated obesity PMC7188666

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00445250 Radiodermatitis PHASE2 UNKNOWN - Rabin Medical Center, Petach T... More >>iqva, 49100, Israel Less <<
NCT05954104 Alopecia Areata COMPLETED 2023-10-15 Faculty of Dentistary - Aswan ... More >>University, Aswan, Egypt Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.12mL

2.42mL

1.21mL

24.24mL

4.85mL

2.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories